Where each peptide stands with the FDA, compounding rules and sport, with a dated source for every change.
Weekly alerts when a peptide's status changes. Unsubscribe anytime. Sent by Eric A Pierra, DC.
| Peptide | FDA | 503A |
|---|---|---|
| Semaglutide | Approved (Ozempic, Rybelsus, Wegovy, Wegovy tablets) | Component of an approved drug, limited by FDA 'essentially a copy' rules |
| Tirzepatide | Approved (Mounjaro, Zepbound) | Component of an approved drug, limited by copy rules |
| BPC-157 | Not approved | No pathway. In no category since Apr 22, 2026 |
| TB-500 | Not approved | No pathway. In no category since Apr 22, 2026 |
| KPV | Not approved | No pathway (per MDside note) |
| MOTS-c | Not approved | No pathway. In no category since Apr 22, 2026 |
| Epitalon | Not approved | No pathway. In no category since Apr 22, 2026 |
| Semax | Not approved in the US | No pathway. In no category since Apr 22, 2026 |
| Emideltide (DSIP) | Not approved | No pathway (per MDside note) |
| Ipamorelin | Not approved | No pathway. Committee voted 0-12 against, Oct 2024 |
| CJC-1295 | Not approved | No pathway. Committee voted against all five forms |
| Sermorelin | Formerly approved (Geref); withdrawn 2009, not for safety | Compounded as approved-drug component (caveats apply) |
| Tesamorelin | Approved (Egrifta); regulated as a biologic since Mar 23, 2020 | No pathway; biologics are outside 503A |
| GHK-Cu | Not approved | Topical: returning to Category 1. Injectable: no pathway |
| NAD+ | Not approved | Category 1 (NAD, NADH) under interim policy |
| Retatrutide | Investigational (Eli Lilly) | No pathway; FDA says it cannot be compounded |
| PT-141 (bremelanotide) | Approved (Vyleesi, 2019) | Component of an approved drug, limited by copy rules |
| Selank | Not approved | No pathway. In no category since Sep 2024 |
| Thymosin alpha-1 | Not approved in the US | No pathway. Committee voted 4-17 against |
| AOD-9604 | Not approved | No pathway. Committee voted 0-12 against |
| Oxytocin | Approved (Pitocin and generics) | Component of an approved drug, limited by copy rules |
Not medical or legal advice. PeptideStatus summarizes public regulatory sources for education only. It does not recommend using any substance. Rules change and vary by state. Talk to a licensed clinician and counsel. Status data verified only as of the source dates shown; Oct 19, 2026 build.